X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-02-23 | VERA | Vera Therapeutics, Inc. | Brenner Robert | Chief Medical Officer | S - Sale | $41.98 | -2,151 | 50,947 | -4% | -$90,307 | ||||||
2026-02-23 | VERA | Vera Therapeutics, Inc. | Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR | S - Sale | $41.98 | -3,117 | 64,722 | -5% | -$130,864 | ||||||
2026-02-23 | VERA | Vera Therapeutics, Inc. | Grant Sean | CFO | S - Sale | $41.98 | -4,949 | 119,181 | -4% | -$207,778 | ||||||
2026-02-23 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Pres, CEO | S - Sale | $41.98 | -16,925 | 479,193 | -3% | -$710,578 | ||||||
2026-02-23 | VERA | Vera Therapeutics, Inc. | Johnson David Lee | COO | S - Sale | $41.98 | -2,579 | 45,727 | -5% | -$108,276 | ||||||
2026-02-23 | VERA | Vera Therapeutics, Inc. | Turner William D. | Chief Regulatory Officer | S - Sale | $41.98 | -2,187 | 45,313 | -5% | -$91,819 | ||||||
2026-02-23 | VERA | Vera Therapeutics, Inc. | Skelton Laurence Matthew | Chief Commercial Officer | S - Sale | $41.98 | -1,582 | 64,218 | -2% | -$66,419 | ||||||
2026-02-23 | OCUL | Ocular Therapeutix, Inc | Dugel Pravin | See Remarks | S - Sale | $8.28 | -20,056 | 3,313,137 | -1% | -$166,064 | ||||||
2026-02-23 | OCUL | Ocular Therapeutix, Inc | Kaiser Peter | Chief Development Officer | S - Sale | $8.28 | -2,810 | 269,108 | -1% | -$23,267 | ||||||
2026-02-23 | OCUL | Ocular Therapeutix, Inc | Heier Jeffrey S. | Chief Scientific Officer | S - Sale | $8.28 | -3,057 | 323,368 | -1% | -$25,312 | ||||||
2026-02-23 | OCUL | Ocular Therapeutix, Inc | Nayak Sanjay | Chief Strategy Officer | S - Sale | $8.28 | -1,759 | 330,653 | -1% | -$14,565 | ||||||
2026-02-23 | ARVN | Arvinas, Inc. | Loomis David K | Chief Accounting Officer | S - Sale | $12.16 | -1,108 | 29,692 | -4% | -$13,473 | ||||||
2026-02-23 | ARVN | Arvinas, Inc. | Cacace Angela M | Chief Scientific Officer | S - Sale | $12.16 | -3,609 | 147,623 | -2% | -$43,885 | ||||||
2026-02-23 | ARVN | Arvinas, Inc. | Teel Randy | Pres, CEO | S - Sale | $12.16 | -4,786 | 149,696 | -3% | -$58,198 | ||||||
| D | 2026-02-25 | UTHR | United Therapeutics Corp | Causey Christopher | Dir | S - Sale+OE | $520.00 | -1,000 | 4,190 | -19% | -$520,000 | |||||
| D | 2026-02-24 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale+OE | $6.26 | -41,666 | 1,861,517 | -2% | -$260,621 | |||||
2026-02-24 | COCP | Cocrystal Pharma, Inc. | Frost Phillip Md Et Al | Dir, 10% | P - Purchase | $1.00 | +20,000 | 1,935,651 | +1% | +$19,952 | ||||||
2026-02-23 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $45.32 | -34,791 | 229,690 | -13% | -$1,576,606 | ||||||
| M | 2026-02-23 | IRWD | Ironwood Pharmaceuticals Inc | John Minardo | GC | S - Sale | $3.73 | -36,492 | 363,886 | -9% | -$136,177 | |||||
| M | 2026-02-23 | IRWD | Ironwood Pharmaceuticals Inc | Shetzline Michael | SVP, CMO, Head-Res, Drug | S - Sale | $3.73 | -32,582 | 1,059,862 | -3% | -$121,586 | |||||
| M | 2026-02-23 | IRWD | Ironwood Pharmaceuticals Inc | Gaskins Tammi L | Chief Commercial Officer | S - Sale | $3.73 | -21,526 | 213,738 | -9% | -$80,328 | |||||
| M | 2026-02-23 | IRWD | Ironwood Pharmaceuticals Inc | McCourt Thomas A | CEO | S - Sale | $3.73 | -198,283 | 1,489,002 | -12% | -$739,929 | |||||
| M | 2026-02-23 | IRWD | Ironwood Pharmaceuticals Inc | Martini Gregory S. | CFO | S - Sale | $3.73 | -21,944 | 160,601 | -12% | -$81,888 | |||||
| M | 2026-02-23 | IRWD | Ironwood Pharmaceuticals Inc | Silver Ronald | Principal Accounting Officer | S - Sale | $3.73 | -24,173 | 252,636 | -9% | -$90,206 | |||||
| D | 2026-02-24 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale+OE | $155.77 | -24,774 | 51,871 | -32% | -$3,859,157 | |||||
2026-02-23 | AMLX | Amylyx Pharmaceuticals, Inc. | Mazzariello Gina | GC | S - Sale | $14.14 | -3,419 | 141,274 | -2% | -$48,352 | ||||||
2026-02-23 | LXRX | Lexicon Pharmaceuticals, Inc. | Debbane Raymond | Dir | P - Purchase | $1.47 | +100,000 | 51,658,909 | 0% | +$147,000 | ||||||
| D | 2026-02-23 | KALV | Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | CHIEF MEDICAL OFFICER | S - Sale+OE | $15.57 | -5,354 | 138,983 | -4% | -$83,345 | |||||
| D | 2026-02-23 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $15.57 | -10,034 | 442,883 | -2% | -$156,197 | |||||
| D | 2026-02-23 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $15.57 | -4,347 | 226,701 | -2% | -$67,669 | |||||
| D | 2026-02-23 | KALV | Kalvista Pharmaceuticals, Inc. | Sweeny Nicole | Chief Commercial Officer | S - Sale+OE | $15.57 | -3,975 | 47,003 | -8% | -$61,878 | |||||
| D | 2026-02-23 | KALV | Kalvista Pharmaceuticals, Inc. | Piekos Brian | CFO | S - Sale+OE | $15.57 | -1,767 | 13,762 | -11% | -$27,507 | |||||
| M | 2026-02-20 | MPLT | Maplight Therapeutics, Inc. | Malenka Robert C. | Dir | S - Sale | $18.34 | -14,195 | 356,731 | -4% | -$260,398 | |||||
2026-02-20 | OCUL | Ocular Therapeutix, Inc | Waheed Nadia | Chief Medical Officer | S - Sale | $7.74 | -3,510 | 314,907 | -1% | -$27,167 | ||||||
2026-02-20 | OCUL | Ocular Therapeutix, Inc | Lindstrom Richard L Md | Dir | P - Purchase | $7.66 | +60,229 | 246,933 | +32% | +$461,354 | ||||||
| D | 2026-02-20 | RIGL | Rigel Pharmaceuticals Inc | Moos Walter H | Dir | S - Sale+OE | $36.36 | -4,000 | 12,722 | -24% | -$145,440 | |||||
2026-02-20 | NAMS | Newamsterdam Pharma Co N.V. | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | S - Sale | $35.31 | -45,481 | 53,500 | -46% | -$1,605,998 | ||||||
| D | 2026-02-23 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $472.13 | -14,440 | 2,648 | -85% | -$6,817,499 | |||||
2026-02-23 | VNDA | Vanda Pharmaceuticals Inc. | Honore Tage | Dir | S - Sale | $8.03 | -30,000 | 93,469 | -24% | -$240,900 | ||||||
| D | 2026-02-20 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO | S - Sale+OE | $30.10 | -60,000 | 432,886 | -12% | -$1,805,766 | |||||
2026-02-20 | ARDX | Ardelyx, Inc. | Mott David M | Dir | P - Purchase | $5.84 | +333,333 | 3,302,918 | +11% | +$1,946,331 | ||||||
2026-02-20 | ARDX | Ardelyx, Inc. | Bishop John E | See Remarks | S - Sale | $5.85 | -3,179 | 339,151 | -1% | -$18,586 | ||||||
2026-02-20 | ARDX | Ardelyx, Inc. | Reilly Joseph James | See Remarks | S - Sale | $5.85 | -4,991 | 151,790 | -3% | -$29,181 | ||||||
2026-02-20 | ARDX | Ardelyx, Inc. | Williams Laura A | See Remarks | S - Sale | $5.85 | -8,176 | 436,082 | -2% | -$47,803 | ||||||
2026-02-20 | ARDX | Ardelyx, Inc. | Hohenleitner Susan | CFO | S - Sale | $5.85 | -2,033 | 230,533 | -1% | -$11,886 | ||||||
2026-02-20 | ARDX | Ardelyx, Inc. | Brady James Parker | CHRO | S - Sale | $5.85 | -2,543 | 262,912 | -1% | -$14,868 | ||||||
2026-02-20 | ARDX | Ardelyx, Inc. | Kelliher Mike | See Remarks | S - Sale | $5.85 | -9,595 | 364,666 | -3% | -$56,099 | ||||||
2026-02-20 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $5.85 | -45,982 | 1,882,350 | -2% | -$268,841 | ||||||
2026-02-20 | ARDX | Ardelyx, Inc. | Foster Eric Duane | Chief Commercial Officer | S - Sale | $5.85 | -10,439 | 425,970 | -2% | -$61,034 | ||||||
| DM | 2026-02-19 | ROIV | Roivant Sciences Ltd. | Torti Frank | Pres, Vant Chair | S - Sale+OE | $27.35 | -3,000,000 | 13,736,547 | -18% | -$82,039,460 | |||||
2026-02-23 | RLYB | Rallybio Corp | Lieber Jonathan I | CFO | S - Sale | $5.06 | -789 | 4,115 | -16% | -$3,992 | ||||||
2026-02-20 | ANIP | Ani Pharmaceuticals Inc | Mutz Christopher | HEAD OF RARE DISEASE | S - Sale | $78.02 | -5,323 | 84,840 | -6% | -$415,300 | ||||||
| M | 2026-02-19 | ANIP | Ani Pharmaceuticals Inc | Davis Krista | SVP, CHRO | S - Sale | $77.74 | -3,814 | 49,263 | -7% | -$296,495 | |||||
2026-02-20 | JNJ | Johnson & Johnson | Schmid Timothy | EVP, WW Chair, MedTech | S - Sale | $245.66 | -1,322 | 26,238 | -5% | -$324,763 | ||||||
2026-02-19 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale | $69.48 | -3,019 | 105,212 | -3% | -$209,763 | ||||||
| D | 2026-02-19 | REGN | Regeneron Pharmaceuticals, Inc. | Zoghbi Huda Y | Dir | S - Sale+OE | $781.33 | -1,638 | 1,703 | -49% | -$1,279,812 | |||||
| D | 2026-02-19 | SUPN | Supernus Pharmaceuticals, Inc. | Sensenig Bethany | Dir | S - Sale+OE | $51.01 | -4,475 | 0 | -100% | -$228,265 | |||||
| D | 2026-02-19 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $150.97 | -10,699 | 585,609 | -2% | -$1,615,257 | |||||
2026-02-19 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $71.39 | -28,053 | 5,388,584 | -1% | -$2,002,717 | ||||||
| M | 2026-02-19 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $50.84 | -14,080 | 39,440 | -26% | -$715,775 | |||||
| D | 2026-02-19 | VRTX | Vertex Pharmaceuticals Inc / Ma | Sachdev Amit | EVP Chief Patient, Ext Af Off | S - Sale+OE | $468.83 | -58,613 | 69,117 | -46% | -$27,479,583 | |||||
| D | 2026-02-19 | EQ | Equillium, Inc. | Zedelmayer Christine | SVP, COO | S - Sale+OE | $1.76 | -185,937 | 191,444 | -49% | -$328,104 | |||||
2026-02-19 | PMN | Promis Neurosciences Inc. | Kaplan Johanne | Chief Development Officer | P - Purchase | $15.35 | +1,629 | 3,941 | +70% | +$25,005 | ||||||
| M | 2026-02-19 | LXRX | Lexicon Pharmaceuticals, Inc. | Debbane Raymond | Dir | P - Purchase | $1.47 | +150,000 | 51,558,909 | 0% | +$219,755 | |||||
| D | 2026-02-12 | TLPH | Talphera, Inc. | Angotti Vincent J. | CEO | P - Purchase | $0.81 | +105,364 | 577,395 | +22% | +$85,587 | |||||
| D | 2026-02-12 | TLPH | Talphera, Inc. | Aslam Shakil | Chief Medical Officer | P - Purchase | $0.81 | +35,000 | 83,178 | +73% | +$28,431 | |||||
| D | 2026-02-12 | TLPH | Talphera, Inc. | Dasu Badri N | Chief Engineering Officer | P - Purchase | $0.81 | +35,000 | 73,884 | +90% | +$28,431 | |||||
| D | 2026-02-12 | TLPH | Talphera, Inc. | Asadorian Raffi | CFO | P - Purchase | $0.81 | +45,000 | 179,579 | +33% | +$36,554 | |||||
2026-02-18 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale | $73.00 | -180 | 21,174 | -1% | -$13,140 | ||||||
2026-02-18 | NKTR | Nektar Therapeutics | Robin Howard W | Pres, CEO | S - Sale | $73.00 | -423 | 75,517 | -1% | -$30,879 | ||||||
| M | 2026-02-18 | MPLT | Maplight Therapeutics, Inc. | Pavlov George | Dir | P - Purchase | $17.65 | +25,000 | 25,000 | New | +$441,168 | |||||
| D | 2026-02-18 | SEPN | Septerna, Inc. | Bhatt Elizabeth | Pres, COO | S - Sale+OE | $28.97 | -4,000 | 174,209 | -2% | -$115,860 | |||||
2026-02-18 | PTCT | Ptc Therapeutics, Inc. | Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | S - Sale | $69.36 | -2,494 | 70,199 | -3% | -$172,984 | ||||||
2026-02-18 | PTCT | Ptc Therapeutics, Inc. | Gravier Pierre | CFO | S - Sale | $69.36 | -2,992 | 87,318 | -3% | -$207,525 | ||||||
2026-02-18 | PTCT | Ptc Therapeutics, Inc. | Pauwels Eric | CHIEF BUSINESS OFFICER | S - Sale | $69.36 | -3,019 | 77,122 | -4% | -$209,398 | ||||||
2026-02-18 | PTCT | Ptc Therapeutics, Inc. | Klein Matthew B. | CEO | S - Sale | $69.36 | -7,371 | 387,082 | -2% | -$511,253 | ||||||
2026-02-18 | PTCT | Ptc Therapeutics, Inc. | Golden Lee Scott | EVP, CHIEF MEDICAL OFFICER | S - Sale | $69.36 | -2,484 | 89,944 | -3% | -$172,290 | ||||||
2026-02-18 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale | $69.36 | -3,121 | 118,866 | -3% | -$216,473 | ||||||
2026-02-18 | PLYX | Polaryx Therapeutics, Inc. | Landis G. Michael | CFO | P - Purchase | $2.79 | +2,867 | 228,225 | +1% | +$7,991 | ||||||
2026-02-18 | RCKT | Rocket Pharmaceuticals, Inc. | Militello John | See Remarks | S - Sale | $3.34 | -1,157 | 91,019 | -1% | -$3,862 | ||||||
2026-02-18 | ANNX | Annexon, Inc. | Dananberg Jamie | Chief Medical Officer | S - Sale | $5.10 | -5,290 | 73,152 | -7% | -$26,979 | ||||||
2026-02-18 | ANNX | Annexon, Inc. | Lew Jennifer | EVP, CFO | S - Sale | $5.11 | -7,851 | 113,765 | -6% | -$40,119 | ||||||
2026-02-18 | ANNX | Annexon, Inc. | Artis Dean Richard | EVP, CHIEF SCIENTIFIC OFFICER | S - Sale | $5.10 | -5,290 | 123,487 | -4% | -$26,979 | ||||||
2026-02-18 | ANNX | Annexon, Inc. | Yednock Ted | EVP, CHIEF INNOVATION OFFICER | S - Sale | $5.11 | -7,857 | 97,227 | -7% | -$40,149 | ||||||
2026-02-18 | ANNX | Annexon, Inc. | Overdorf Michael | EVP, CHIEF BUSINESS OFFICER | S - Sale | $5.10 | -6,225 | 124,464 | -5% | -$31,748 | ||||||
2026-02-18 | RCKT | Rocket Pharmaceuticals, Inc. | Shah Gaurav | CEO | S - Sale | $3.34 | -5,990 | 1,452,293 | 0% | -$19,995 | ||||||
2026-02-19 | KROS | Keros Therapeutics, Inc. | Seehra Jasbir | CEO | S - Sale | $16.17 | -7,015 | 385,708 | -2% | -$113,433 | ||||||
2026-02-18 | KROS | Keros Therapeutics, Inc. | Lerner Lorena Raquel | Chief Science Officer | S - Sale | $16.35 | -3,873 | 31,127 | -11% | -$63,324 | ||||||
2026-02-18 | KROS | Keros Therapeutics, Inc. | Cho Esther | SVP, GC | S - Sale | $16.35 | -4,745 | 39,755 | -11% | -$77,581 | ||||||
2026-02-18 | KROS | Keros Therapeutics, Inc. | Regnante Keith | CFO | S - Sale | $16.35 | -4,739 | 39,261 | -11% | -$77,483 | ||||||
2026-02-18 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $3.34 | -1,376 | 682,000 | 0% | -$4,593 | ||||||
| D | 2026-02-19 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale+OE | $16.00 | -100 | 162,894 | 0% | -$1,600 | |||||
| D | 2026-02-18 | PVLA | Palvella Therapeutics, Inc. | Goin Kathleen | COO | S - Sale+OE | $79.40 | -4,302 | 0 | -100% | -$341,564 | |||||
2026-02-18 | ALXO | Alx Oncology Holdings Inc | Pinto Shelly | SVP, Finance, CAO | S - Sale | $2.27 | -565 | 87,708 | -1% | -$1,283 | ||||||
| M | 2026-02-17 | RYTM | Rhythm Pharmaceuticals, Inc. | Smith Hunter C | CFO | S - Sale | $101.31 | -7,954 | 110,512 | -7% | -$805,814 | |||||
| D | 2026-02-18 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $15.00 | -1,038 | 429,667 | 0% | -$15,570 | |||||
| D | 2026-02-18 | KALV | Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | CHIEF MEDICAL OFFICER | S - Sale+OE | $15.00 | -1,163 | 133,087 | -1% | -$17,445 | |||||
| D | 2026-02-18 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $15.00 | -1,109 | 224,173 | 0% | -$16,635 | |||||
2026-02-18 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $29.35 | -10,916 | 658,705 | -2% | -$320,373 | ||||||
| D | 2026-02-17 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Chief Scientific Officer | S - Sale+OE | $29.02 | -8,500 | 393,075 | -2% | -$246,655 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |